Ubiquitin protein may treat variety of diseases from Parkinson's to diabetes

Ubiquitin's novel forms suggest novel functions

A tiny protein called ubiquitin - so named because it is present in every cell of living things as dissimilar as hollyhocks and humans - may hold the key to treatment for a variety of diseases from Parkinson's to diabetes. The protein, found in all eukaryotes (organisms with membranous cells), was considered unimportant when it was described in 1975. But scientists now know ubiquitin takes many different forms and is important in basic cellular processes, from controlling cells' circadian clocks to clearing away the harmful build-up of cells found in cancer and other diseases.

To maximize ubiquitin's potential for treating diseases, researchers are working to identify the protein's dizzying array of structures, and to understand each form's function. Ubiquitin forms polymeric chains linked by specific amino acids. Each ubiquitin protein can connect to its neighbor through one of eight different amino acids, and each combination appears to do something different in a normal cell, says University of Maryland structural biologist David Fushman, whose lab studies these ubiquitin chains and their linkages.

Imagine the cell as a dance floor, thronged with proteins seeking partners, says Fushman, who has studied ubiquitin since 2000. When two ubiquitins join through a lysine, "it's like two hands meeting, but with just a single finger touching that's specific to that lysine." The choice of lysine determines the shape of the ubiquitin chain, and probably also determines its function.

Fushman and his colleagues' newly published research focuses on one of the most common and least studied linkages, the polymeric chain formed by the amino acid Lysine-11. The ubiquitin chains linked by Lysine-11 "are directly involved in cell cycle regulation," Fushman says. To turn that knowledge into medically useful information, "we have to understand exactly how they form and with whom they interact."

Most work of this type is done in a test tube and uses x-ray crystallography to map the structures. Fushman's lab uses a different method that he says produces an environment somewhat closer to nature. The team used nuclear magnetic resonance spectroscopy (NMR) and other techniques to map the Lysine-11-linked chains.

The researchers found these chains take on a different shape in solution than in crystals, and are more flexible than was previously thought. Ubiquitin chains linked via Lysine-11 can form various three-dimensional shapes, and as salt concentrations change, the chains' shape also changes, the team found.

Researcher Carlos Casta-eda and others in the Fushman lab reported their results in a paper published July 2 in the biological journal Structure.

The most-studied ubiquitin chain, linked via Lysine-48, is known as a "protein destroyer" because it labels cellular proteins to be broken up for later recycling. The UMD team found the cellular receptors responsible for breaking down proteins interact with Lysine-11 chains, but not as efficiently as with Lysine-48 chains. Therefore protein destruction does not appear to be the main task of the Lysine-11 linked chain, Fushman says; its function is something different and perhaps equally vital to maintaining healthy cells.

Comments

  1. Ralph Allen Ralph Allen United States says:

    ADA Poster Presentation Abstract from the June Chicago convention
    Lorcaserin, (Belviq)  a selective 5-HT2C agonist, was recently approved for weight management in conjunction with lifestyle modification in obese patients (BMI ≥30) and overweight patients (BMI ≥27) with at least one co-morbidity. In patients without diabetes, proportions achieving ≥5% weight loss and absolute weight loss at Week (W)52 for lorcaserin vs. placebo were 47 vs. 23% and 5.8 vs. 2.5kg respectively (MITT-LOCF). In patients with type 2 diabetes mellitus (T2DM) results were 38 vs.16% and 4.7 vs.1.6kg respectively.

    To limit exposure and maximize benefit the predictive value for >5% W52 weight loss was assessed at W12. Patients not losing at least 5% at W12 (non-responders) should be discontinued.

    Proportions of responders without diabetes lorcaserin vs. placebo were 49.3 vs. 22.6%. W52 weight loss in lorcaserin responders without diabetes was 10.6kg (23 lbs) with 86% and 50% achieving at least 5% and 10% weight loss respectively.

    Proportions of responders with T2DM lorcaserin vs. placebo were 35.9 vs. 11.5%. W52 weight loss in lorcaserin responders with T2DM was 9.3kg (20 lbs) with 71% and 36% achieving 5% and 10% weight loss. W52 reductions in FPG and A1C in lorcaserin responders with T2DM were 29.3mg/dL and 1.2%. W52 reductions in systolic and diastolic BP and heart rate were 3.4mmHg 2.5mmHg and 2.5BPM in lorcaserin responders without diabetes and 2.6mmHg 1.9mmHg and
    3.2BPM in lorcaserin responders with T2DM.

    Achievement of ≥5% weight loss by W12 is a strong predictor of robust one-year lorcaserin responses in weight cardiovascular vital signs and glycemia.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients